Más noticias
 

COMUNICADO: Xbox establece un récord mundial Guinness desde un globo aerostático personalizado de Super Lucky's Tale

ALBUQUERQUE, Nuevo México, 19 de octubre de 2017 /PRNewswire/ -- ¡Bienvenidos a la aventura! Anticipándose al estreno mundial de Super Lucky's Tale [https://www.microsoft.com/en-us/store/p/super-luckys-tale/9plmgfwcfz9g], el 7 de noviembre, Xbox creó un globo aerostático personalizado de Super Lucky's Tale que echó a volar durante el Albuquerque International Balloon Fiesta® y los aficionados de todo el mundo pudieron ver la transmisión en directo desde una altura de 1200 pies en el canal Mixer Xbox [https://mixer.

COMUNICADO: dB MAGIX se estrena en la Feria de Electrónica de Global Sources con sus modernos accesorios de audio Hi-Fi digitales

HONG KONG, 18 de octubre de 2017 /PRNewswire/ -- dBMAGIX Technology (dBMAGIX o "la empresa"), empresa fabricante de aparatos de audio, se estrena a escala mundial en la Feria de Electrónica Móvil de Global Sources (METF, por sus siglas en inglés, o "la Feria") celebrada en Hong Kong.

COMUNICADO: ZTE obtiene un 36,58 % más de beneficios netos en 9 meses

Previsión de beneficios netos totales de 4300 a 4800 millones de RMB en todo el año SHENZHEN, China, 18 de octubre de 2017 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ), un importante proveedor de soluciones tecnológicas de telecomunicaciones, empresariales y de consumo para Internet móvil, ha publicado una nota orientativa sobre un aumento del 36,58 % en sus beneficios netos en el período de 9 meses que finalizó el 30 de septiembre de 2017.

COMUNICADO: VOCOlinc trae nuevos productos para el hogar inteligente a la Feria de Electrónica Móvil de Global Sources

Productos vanguardistas galardonados como Elección del Analista en el mayor evento de electrónica móvil del mundo HONG KONG, 18 de octubre de 2017 /PRNewswire/ -- El líder en innovación en la automatización del hogar, VOCOlinc, hizo un debut de alto nivel en la Feria de Electrónica Móvil de Global Sources (METF, por sus siglas en inglés, o "la Feria") presentando con orgullo sus nuevos productos para el hogar inteligente.

COMUNICADO: CEM presenta el futuro de la preparación de muestras moleculares

MATTHEWS, Carolina del Norte, 18 de octubre de 2017 /PRNewswire/ -- CEM Corporation, proveedor líder de sistemas de preparación de muestras, se complace en presentar el nuevo sistema de extracción EDGE(TM) para la preparación rápida de muestras de cromatografía gaseosa (CG) y cromatografía líquida (CL).

COMUNICADO: En 'Behind the Wheel', CNH Industrial y el Royal College of Art organizan un concurso de diseño innovador y sostenible

Eche un vistazo a las brillantes ideas de diseño industrial ganadoras de los jóvenes talentos en el nuevo episodio web de 'Behind the Wheel' de CNH Industrial, que puede verse online en cnhindustrial.com/behindthewheel [http://cnhindustrial.com/behindthewheel] LONDRES, 18 de octubre de 2017 /PRNewswire/ -- Desde un aerodeslizador de rescate a un vehículo construido para ser eficaz tanto en estaciones secas como húmedas, los estudiantes de los programas de diseño de vehículos y servicios del Royal College of Art's (RCA), dieron lo mejor a la hora de responder a la convocatoria del concurso de CNH Industrial.

COMUNICADO: Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 (1)

DARMSTADT, Germany, October 18, 2017 /PRNewswire/ -- Not intended for US/UK based media Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017   - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad   - Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS criteria in predicting clinical outcomes out to 15 years   - Pre-clinical data for investigational evobrutinib highlight potential role in patients with relapsing MS   - A total of 40 abstracts will be presented by lead investigators   Merck, a leading science and technology company, today announced that data for approved and investigational multiple sclerosis (MS) treatments, MAVENCLAD(R)(Cladribine Tablets) and Rebif(R) (interferon beta-1a) and evobrutinib will be presented at MSParis 2017, 7th Joint ECTRIMS-ACTRIMS Meeting, 25-28 October 2017 in Paris, France.

COMUNICADO: Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 (2)

MAVENCLAD (Cladribine Tablets) Presentations Abstract/ Presentation Title Lead Author Poster # Date/Time/Session Effects of Cladribine Tablets on CD4+ T Cell Subsets in the ORACLE-MS Poster Session 1 Study: Results from an Thursday 26 October Analysis of Lymphocyte 2017 Surface Markers Stuve O P667 Time: 15:30-17:00 Cladribine Tablets Produce Selective and Discontinuous Reduction of B and T Lymphocytes and Natural Killer Cells in Patients with Early and Relapsing Multiple Sclerosis (ORACLE-MS,CLARITY and CLARITY Extension) Stuve O P690 Rates of Lymphopenia Year-by-year in Patients with Relapsing Multiple Sclerosis Treated and Retreated with Cladribine Tablets 3.5mg/kg Cook S P666 Long-Term Lymphocyte Counts in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B and T Cell Soelberg-Sorensen Subsets P P655 Effects of Cladribine Poster Session 2 Tablets on Radiological Friday 27 October 2017 Outcomes in High Disease Time: 15:30-17:00 Activity (HDA) Subgroups of Patients with Relapsing Poster Session 2 Multiple Sclerosis (RMS) Friday 27 October 2017 in the CLARITY Study Giovannoni G P1164 Time: 15:30-17:00 Proportions of Patients with Highly Active RMS Achieving No Evidence of Disease Activity (NEDA) in Response to Cladribine Tablets in CLARITY Giovannoni G P1143 Investigation of Cladribine Treatment Rules in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) by means of Modelling & Simulation Terranova N P912 Infections During Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5 mg/kg: Data from an Integrated Safety Analysis Cook S P1142 Innate Immune Cell Counts in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets 3.5 mg/kg in CLARITY and CLARITY Soelberg- Extension Sorensen P P1141 An analysis of malignancy Late-breaker risk in the clinical Poster Session 2 development programme of Friday 27 October 2017 cladribine tablets in Time: 15:30-17:00 patients with relapsing multiple sclerosis (RMS) Galazka A P1878 Pregnancy outcomes during Late-breaker the clinical development Poster Session 2 programme of cladribine in Friday 27 October 2017 multiple sclerosis (MS): Time: 15:30-17:00 an integrated analysis of safety for all exposed patients Galazka A P1874 Rebif (interferon beta-1a) Presentations Abstract/ Presentation Title Lead Author Poster # Date/Time/Session Disease Activity as Poster Session 1 Assessed by the MAGNIMS Thursday 26 October Score Predicts Long-Term 2017 Clinical Disease Activity Time: 15:30-17:00 Free Status and Disability Poster Session 1 Progression in Patients Thursday 26 October Treated with Subcutaneous 2017 Interferon Beta-1a Sormani MP P770 Time: 15:30-17:00 The Association between Disease Activity and Disability Progression in Patients with Relapsing-Remitting Multiple Sclerosis Spelman T P348 Clinical Characteristics and Treatment Patterns of Relapsing-Remitting Multiple Sclerosis Patients with High Disease Activity Spelman T P340 Comparing patient and healthcare professional perceptions on multiple sclerosis management and care where do their priorities differ? Results from a qualitative survey Rieckman P P814 Infertility Diagnosis and Treatment in Women With and Without Multiple Sclerosis Houtchens MK AP356 Validation of MUSIQOL among Arabic-speaking MS Patients treated with High dose INF-beta 1a sc injection New Formulation Al Jumah M P821 RebiQoL: A telemedicine patient support program on health related quality of life and adherence in MS patients treated with Rebif Landtblom AM P826 Serum Neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS Barro C P636 Impact of the Presence of Poster Session 2 Gadolinium-Enhancing Friday 27 October 2017 Lesions at Baseline on No Time: 15:30-17:00 Evidence of Disease Poster Session 2 Activity Status in Friday 27 October 2017 Patients Treated with Time: 15:30-17:00 Subcutaneous Interferon Beta-1a: A Post-Hoc Analysis of REFLEXION Freedman M P1144 Evolution of New Lesions and its Temporal Patterns in Patients with Clinically Isolated Syndrome Treated with Subcutaneous Interferon Beta-1a Vrenken H P1025 Using algorithms to identify High Disease Activity Relapsing-Remitting Multiple Sclerosis patients using electronic health record data with natural language processing Kamauu AW P877 Using United States Integrated Delivery Network (IDN) Electronic Health Records (EHR)/Natural Language Processing (NLP)-Based Algorithms to Identify Relapses in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Kamauu AW P885 Developing United States Integrated Delivery Network (IDN) Claims-Based Algorithms to Identify Relapses in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Kamauu AW P878 Rates of Pregnancy in Women With and Without Multiple Sclerosis Over Time Houtchens MK P890 Prevalence of Comorbidities in Patients With and Without Multiple Sclerosis by Age and Sex: A US Retrospective Claims Database Analysis Kresa-Reahl K P941 Infertility Treatment and Live Birth Rates in Women With and Without Multiple Sclerosis Houtchens MK P891 An Evaluation of Adherence Using Panel Survey Data From Patients With Multiple Sclerosis Treated With Subcutaneous Interferon beta-1a or Dimethyl Fumarate Perrin Ross A P1251 Real-World Assessment of Relapse in Patients With Multiple Sclerosis Newly Initiating scIFNbeta1a Compared With Oral Disease-Modifying Drugs Bowen J P1245 Interferon-beta and regulatory cells: evaluation of treatment-induced modulation of Treg, Breg and CD56bright NK cell levels in multiple sclerosis patients Martire S P1140 Risk of stroke in patients Late-breaker with multiple sclerosis Poster Session 2 treated with subcutaneous Friday 27 October 2017 interferon beta-1a Venkatesh S P1918 Time: 15:30-17:00 Creating a healthcare claims-based adaptation of Kurtzke Functional Systems Scores for assessing multiple sclerosis severity and progression Le Truong CTL EP1767 ePosters A mapping study to compare the educational offerings for patients in the fields of multiple sclerosis and HIV in Europe and Canada Rieckman P EP1838 Long-term real-life retrospective analysis on interferon beta1-a use in RRMS patients in Finland Al Jumah M EP1687 Adherence, cognition and behavioral performance in relapsing-remitting MS (RRMS) patients using the electronic autoinjector RetainSmartTM: 1 and 2 year follow-up from the German multicenter RETAINsmart study Rau D EP1692 Cerebrospinal fluid levels of neurofilament light chain, C-X-C ligand motif 13, and chitinase-3-like protein 1 reflect distinct pathological processes in multiple sclerosis Zanoni M EP1598 Brain atrophy and disease free status over 3 years in multiple sclerosis patients under interferon beta 1a subcutaneous treatment Rojas JI EP1657 Evobrutinib Presentations Abstract/ Presentation Title Lead Author Poster # Date/Time/Session Oral Presentation B cell-mediated Parallel Session 8: experimental CNS Immune Cells in Injury autoimmunity is modulated and Repair by inhibition of Bruton's Thursday 26 October 2017 tyrosine kinase Torke S 143 14:00-15:30 Design of a Phase II Dose Poster Session 1 Range Finding, Efficacy Thursday 26 October 2017 and Safety Study of the Time: 15:30-17:00 Bruton's Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Relapsing Multiple Sclerosis Patients Montalban X P675 T cell mediated experimental CNS autoimmunity induced by PLP in SJL mice is modulated by Evobrutinib (M2951) a novel Bruton's tyrosine kinase inhibitor Boschert U P678 About MAVENCLAD(R)    MAVENCLAD(R) (cladribine tablets) is approved in the European Union for the treatment of highly active relapsing multiple sclerosis[*] (RMS).

COMUNICADO: Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 (3)

About Evobrutinib   Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). It is an oral, highly selective inhibitor of Bruton's Tyrosine Kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages.

COMUNICADO: Preparándose para el disparo de salida: Gree - Tour de Guangxi 2017, el único tour ciclista internacional de Asia

Pekín, 18 de octubre de 2017 /PRNewswire/ -- La prueba ciclista "Gree World Road Cycling Tour of Guangxi" (Tour de Guangxi), un acontecimiento organizado por el gobierno popular de la región autónoma de Guangxi Zhuang y el grupo Wanda Sports Group, y que se sitúa a la par del Tour de Francia, el Giro de Italia, y la Vuelta a España, se celebrará en Guangxi del 19 al 24 de octubre.

COMUNICADO: XCMG logra un crecimiento fuera de China del 84,83 por ciento en la primera mitad de 2017

Rodeado de una demanda cada vez mayor, XCMG gana participación de mercado en los países de la Iniciativa Cinturón y Ruta de la Seda XUZHOU, China, 18 de octubre de 2017 /PRNewswire/ -- XCMG (SHE: 000425), el fabricante líder mundial de maquinaria de construcción, ha publicado su informe semestral, que recoge que la empresa ha logrado un crecimiento en facturación del 77,44 por ciento y ha experimentado un aumento de los beneficios netos del 333,27 interanual.

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies